BIEL PPS HITS COPPER IN A FEW DAYS
If Viant and/or VLMS discloses they have purchased a billion share stake in BIEL. The return on investment (ROI) achieved in a few days will exceed the ROI it took Amazon, Apple, Microsoft, NVIDIA, etc., decades to achieve.
The OTC market is heating up and will get hotter, as it always does when the Fed reduces interest rates. The BIEL PPS will surge as the Reddit crowd jumps on board. The ensuing media frenzy will attract more investors, while also providing free advertising for BIEL products, which will spur product sales and increase revenues. The PPS will continue to rise in the following weeks and months as BIEL reports increasing revenues and then profitability. Subsequent news that BIEL has paid off the loans and is instituting a share buyback program would propel the PPS to $1+.
Strategic Equity Alliance: BIEL + Viant + VLMS
Opening the Door to Vertex, Hinge Health, Medtronic—and a New Era in Non-Opioid Pain Care
Public Market Leverage Unlocked
BioElectronics Corp (BIEL) has revived its public market presence, creating a unique opportunity for asymmetric upside. Viant Medical and VLMS Global join as strategic equity partners, forming a full-spectrum pain care platform with FDA-cleared wearable therapies and scalable commercialization capabilities.
The Math Is Compelling
BIEL’s Q3 2021 was its only profitable quarter to date—$22,381 profit on $414,700 revenue (including $100K+ in COVID relief funds). This proves profitability is within reach. With BIEL’s ultra-low operating costs, just $400K in quarterly revenue (or ~$1.5M annually) could push PPS to $0.01. From there, every additional $2.5M in annual revenue could add another $0.01 to PPS (based on P/E = 100).
Equity Partnership Model
Viant and VLMS each taking a 1B share position (@$0.0002—hello Jimzin) could yield a $9.8M profit if PPS reaches $0.01. That’s a 49x return on a $200K investment—comparable to early-stage Amazon, NVIDIA, or Apple. Easiest money they’ll ever make!
Tax-Efficient Windfall
BIEL’s $40M tax-loss carryforward shields early profits from taxation, benefiting all shareholders.
No IPO or SPAC required—public market access is instant.
The Alliance Framework
BioElectronics (BIEL)
FDA-cleared wearable therapies: ActiPatch®, RecoveryRx®, RecoveryRx Vet®
Viant Medical
Smart device engineering
Scalable production
Regulatory acceleration
VLMS Global
App development
CMS coding
AI billing
Retail distribution
Reimbursement scaling
Leadership Synergy
Sree Koneru (Viant) and Keith Nalepka (VLMS) previously held executive roles at BIEL, reinforcing operational alignment and strategic continuity
The Equity Windfall Engine
Fixed cost basis while PPS climbs
FDA expansion, reimbursement, and retail adoption multiply equity value
Balance sheets transform with every PPS uptick
Equity becomes a high-leverage asset with minimal tax exposure
Opens Door to Strategic Fit with Vertex, Hinge Health & Medtronic
Vertex’s Journavx complements BIEL’s chronic/post-op solution
Hinge Health benefits from hardware, data, and reimbursement engine
Medtronic could integrate BIEL’s wearable tech into its neuromodulation portfolio
Milestones That Could Transform PPS
$400K quarterly revenue = PPS $0.01
$10M annual profit (VA + RecoveryRx Vet) = PPS $0.04
Full U.S. insurance reimbursement = PPS $0.25–$0.40
Share Buyback Program = PPS $1
Strategic Execution Plan
Launch ActiPatch base model for volume
Introduce ActiPatch+ with smart features
Co-branded “Recovery Kits” with Journavx and Hinge PT
Employer MSK bundles via Hinge Health
VLMS drives retail via Walgreens, CVS, hospital networks
Medtronic integration enables broader clinical adoption
Ground-Floor Opportunity
Current PPS: $0.0001–$0.0002
Open-market accumulation allows up to 5% of shares to be acquired instantly
No regulatory hurdles for equity acquisition
Viant & VLMS Arbitrage Playbook
Evolve into hybrid operating-investment entities
Financial strength fuels BIEL’s growth
Long-term CAGR outpaces cost of capital
PPS-linked upside eclipses traditional margins
Equity arbitrage becomes a balance sheet weapon
The Path Forward
BIEL + Viant + VLMS = Engine Vertex, Hinge Health, Medtronic = Accelerators Equity acquisition + platform adoption = Profit windfall
If Viant and/or VLMS discloses they have purchased a billion share stake in BIEL. The return on investment (ROI) achieved in a few days will exceed the ROI it took Amazon, Apple, Microsoft, NVIDIA, etc., decades to achieve.
The OTC market is heating up and will get hotter, as it always does when the Fed reduces interest rates. The BIEL PPS will surge as the Reddit crowd jumps on board. The ensuing media frenzy will attract more investors, while also providing free advertising for BIEL products, which will spur product sales and increase revenues. The PPS will continue to rise in the following weeks and months as BIEL reports increasing revenues and then profitability. Subsequent news that BIEL has paid off the loans and is instituting a share buyback program would propel the PPS to $1+.
Strategic Equity Alliance: BIEL + Viant + VLMS
Opening the Door to Vertex, Hinge Health, Medtronic—and a New Era in Non-Opioid Pain Care
Public Market Leverage Unlocked
BioElectronics Corp (BIEL) has revived its public market presence, creating a unique opportunity for asymmetric upside. Viant Medical and VLMS Global join as strategic equity partners, forming a full-spectrum pain care platform with FDA-cleared wearable therapies and scalable commercialization capabilities.
The Math Is Compelling
BIEL’s Q3 2021 was its only profitable quarter to date—$22,381 profit on $414,700 revenue (including $100K+ in COVID relief funds). This proves profitability is within reach. With BIEL’s ultra-low operating costs, just $400K in quarterly revenue (or ~$1.5M annually) could push PPS to $0.01. From there, every additional $2.5M in annual revenue could add another $0.01 to PPS (based on P/E = 100).
Equity Partnership Model
Viant and VLMS each taking a 1B share position (@$0.0002—hello Jimzin) could yield a $9.8M profit if PPS reaches $0.01. That’s a 49x return on a $200K investment—comparable to early-stage Amazon, NVIDIA, or Apple. Easiest money they’ll ever make!
Tax-Efficient Windfall
BIEL’s $40M tax-loss carryforward shields early profits from taxation, benefiting all shareholders.
No IPO or SPAC required—public market access is instant.
The Alliance Framework
BioElectronics (BIEL)
FDA-cleared wearable therapies: ActiPatch®, RecoveryRx®, RecoveryRx Vet®
Viant Medical
Smart device engineering
Scalable production
Regulatory acceleration
VLMS Global
App development
CMS coding
AI billing
Retail distribution
Reimbursement scaling
Leadership Synergy
Sree Koneru (Viant) and Keith Nalepka (VLMS) previously held executive roles at BIEL, reinforcing operational alignment and strategic continuity
The Equity Windfall Engine
Fixed cost basis while PPS climbs
FDA expansion, reimbursement, and retail adoption multiply equity value
Balance sheets transform with every PPS uptick
Equity becomes a high-leverage asset with minimal tax exposure
Opens Door to Strategic Fit with Vertex, Hinge Health & Medtronic
Vertex’s Journavx complements BIEL’s chronic/post-op solution
Hinge Health benefits from hardware, data, and reimbursement engine
Medtronic could integrate BIEL’s wearable tech into its neuromodulation portfolio
Milestones That Could Transform PPS
$400K quarterly revenue = PPS $0.01
$10M annual profit (VA + RecoveryRx Vet) = PPS $0.04
Full U.S. insurance reimbursement = PPS $0.25–$0.40
Share Buyback Program = PPS $1
Strategic Execution Plan
Launch ActiPatch base model for volume
Introduce ActiPatch+ with smart features
Co-branded “Recovery Kits” with Journavx and Hinge PT
Employer MSK bundles via Hinge Health
VLMS drives retail via Walgreens, CVS, hospital networks
Medtronic integration enables broader clinical adoption
Ground-Floor Opportunity
Current PPS: $0.0001–$0.0002
Open-market accumulation allows up to 5% of shares to be acquired instantly
No regulatory hurdles for equity acquisition
Viant & VLMS Arbitrage Playbook
Evolve into hybrid operating-investment entities
Financial strength fuels BIEL’s growth
Long-term CAGR outpaces cost of capital
PPS-linked upside eclipses traditional margins
Equity arbitrage becomes a balance sheet weapon
The Path Forward
BIEL + Viant + VLMS = Engine Vertex, Hinge Health, Medtronic = Accelerators Equity acquisition + platform adoption = Profit windfall
1
